^
Association details:
| Biomarker: | RAS wild-type + BRAF wild-type |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Optimal molecular-targeted therapies as first-line treatment for RAS wild-type, right-sided metastatic colorectal cancer from the Analysis and Research in Cancers of the Digestive System (ARCAD) database.
Published date:
05/25/2023
Excerpt:
The OS and PFS were significantly prolonged in pts receiving bevacizumab combination therapy compared to those receiving anti-EGFR antibody combination therapy….For patients with RAS wt or RAS/BRAF wt, right-sided mCRC, bevacizumab combination therapy is preferred first-line treatment.
Secondary therapy:
FOLFOX; FOLFIRI; CAPOX; FOLFOXIRI
DOI:
10.1200/JCO.2023.41.16_suppl.3588
